Non-hormonal drug approved for menopause symptoms

Veoza, also known as fezolinetant, is a non-hormonal treatment approved in several regions, including Australia and Europe, for managing menopause-related hot flashes and night sweats. It works by blocking the neurokinin 3 (NK3) receptor, which is involved in the body’s temperature regulation system.

Mechanism differs from hormonal treatments

Unlike hormonal treatments that compensate for the drop in estrogen during menopause, Veoza targets a different biological pathway. It prevents neurokinin B from sending signals that cause excessive body activity, offering an alternative for those who cannot use hormonal therapies.

Clinical trial results show effectiveness

Clinical trials have shown that Veoza can reduce the frequency of moderate to severe hot flashes and night sweats. Women taking the drug experienced a decrease from about 10 to 12 daily episodes to 4 or 5, compared to 6 or 7 in those receiving a placebo.

Safety concerns in France

In France, the National Agency for Medicines (ANSM) has placed Veoza under surveillance due to reports of serious liver damage. Health authorities recommend liver function tests before starting treatment and regular monitoring during the first nine months.

Cost and availability in Australia

Veoza was approved in Australia in March 2024 at a dose of 45 mg per day. However, it is not covered by the Pharmaceutical Benefits Scheme (PBS), meaning patients must pay between 75 and 80 Australian dollars per month. It is available by prescription and no maximum treatment duration has been set.

Non-hormonal alternative for certain patients

Veoza is considered an alternative for women who cannot use hormonal treatments due to side effects or hormone-dependent cancers. A large survey found that one in ten women with vasomotor symptoms could not use hormonal treatment, emphasizing the need for non-hormonal options.

Long-term safety and newer treatments

While clinical trials show Veoza is effective for up to one year, its long-term safety and effectiveness in complex health scenarios are still being evaluated. Newer drugs like Lynkuet (elinzanetant), which target both NK1 and NK3 receptors, have been approved in some regions and may carry fewer liver risks. Research is ongoing to evaluate these drugs in other patient groups, including men undergoing androgen deprivation therapy for prostate cancer.